Always Remember - Buy The Dip

Sentiment Analysis For LGND

The news is currently generally neutral for LGND.

Based on TextBlob analysis of Yahoo! Finance news summaries for LGND on 2015-04-17.

Yahoo! Finance News for LGND

It's "hip" to be repaired: Viking Therapeutics refiles terms for $20 million IPO
Viking Therapeutics, which is developing drugs to speed hip fracture recovery and treat various metabolic disorders, announced terms for its IPO on Friday. The San Diego, CA based company plans to raise $20 million by offering 2.5 million shares

3 Up and Coming Biotech Stocks to Watch
Source Ligand Pharmaceuticals How hot is biotech these days? The top two exchange trade funds focusing on biotech stocks both more than tripled the performance of the S&P 500 index over

Ligand Pharmaceuticals: Biotech's Jack Of All Trades
C all it a jack of all trades in biotech. Rather than just target a small number of drug therapies,Ligand Pharmaceuticals ( LGND ) focuses on a broad range of assets that address a host of

1 Expensive Biotech Stock Worth Buying

Spectrum Pharmaceuticals' CE-melphalan Under Review - Analyst Blog
Spectrum Pharmaceuticals, Inc .'s SPPI new drug application (NDA) for Captisol enabled melphalan (CE melphalan) was accepted by the FDA for review. The company is looking to get CE melphalan approved for a high dose conditioning treatment prior to

Ligand Pharmaceuticals To Present At ROTH Conference; Webcast At 5:30 PM ET
Ligand Pharmaceuticals To Present At ROTH Conference; Webcast At 5:30 PM ET

Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 15.5% - Tale of the Tape
Ligand Pharmaceuticals Incorporated ( LGND ) was a big mover last session with its shares rising over 15% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This

Notable Two Hundred Day Moving Average Cross - LGND
In trading on Tuesday, shares of Ligand Pharmaceuticals Inc (Symbol LGND) crossed below their 200 day moving average of $55.44, changing hands as low as $55.09 per share. Ligand Pharmaceuticals Inc shares are currently trading down about 1.9% on

Ligand Pharma To Present At RBC Capital Markets Conference; Webcast At 4:05 PM
Ligand Pharma To Present At RBC Capital Markets Conference; Webcast At 4:05 PM

Glaxo Submits Another Revolade Application in the EU - Analyst Blog
GlaxoSmithKline ( GSK ) announced that it has submitted another marketing application for Revolade in the EU. The company is looking to get the drug approved for the treatment of pediatric patients (aged 1 year and above) suffering from

Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings - Tale of the Tape
Ligand Pharmaceuticals Incorporated ( LGND ), a biopharmaceutical company follows a business model focused on the development of royalty generating assets using its Captisol formulation technology. This La Jolla, CA based company is well known for its key partnered

Ligand Pharma. To Present At BIO CEO Conference; Webcast At 11:00 AM ET
Ligand Pharma. To Present At BIO CEO Conference; Webcast At 11:00 AM ET

Ligand Pharma Q4 Profit Rises - Quick Facts
Ligand Pharma Q4 Profit Rises - Quick Facts

Ligand Pharmaceuticals Q4 14 Earnings Conference Call At 9:00 AM ET
Ligand Pharmaceuticals Q4 14 Earnings Conference Call At 9:00 AM ET

Ritter Pharma Appoints Matthew Foehr To Board - Quick Facts
Ritter Pharma Appoints Matthew Foehr To Board - Quick Facts

Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4? - Analyst Blog
Ligand Pharmaceuticals Incorporated ( LGND ) is scheduled to report fourth quarter 2014 results before the opening bell on Feb 9, 2015. Ligand Pharma beat estimates in two of the past three quarters. The average earnings surprise over the

AMGN's Biosimilar Matches Blockbuster, PFE Gets FDA Nod, LGND Does A Deal
AMGN's Biosimilar Matches Blockbuster, PFE Gets FDA Nod, LGND Does A Deal

Ligand Pharma Inks License Deal With Sermonix For Lasofoxifene - Quick Facts
Ligand Pharma Inks License Deal With Sermonix For Lasofoxifene - Quick Facts

Ligand Promotes Matthew Foehr To President
Ligand Promotes Matthew Foehr To President

Ligand Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for LGND
In trading on Monday, shares of Ligand Pharmaceuticals Inc (Symbol LGND) crossed above their 200 day moving average of $56.27, changing hands as high as $56.60 per share. Ligand Pharmaceuticals Inc shares are currently trading up about 3.3% on

Spectrum/Ligand Pharma Seek FDA Nod for CE-Melphalan - Analyst Blog
Spectrum Pharmaceuticals, Inc. ( SPPI ) announced the submission of a new drug application (NDA) to the FDA for Captisol enabled melphalan (CE melphalan) HCl for injection (propylene glycol free). The company is looking to get CE melphalan approved

Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Shares of Ligand Pharmaceuticals Incorporated ( LGND ) gained slightly (0.48%) immediately after the company reported third quarter 2014 results. However, shares fell 4.3% in the subsequent trading session. Overall, shares are down 3.9% since the release of third

Sector Update: Health Care
Health care shares were generally flat in pre market trade Monday. In health care stocks news, Merck & Company ( MRK ) a pharmaceutical company, reported Q3 results that beat the Street view on EPS but missed on total

Sector Update: Health-Care Shares Flat Before Opening Bell
Top Health care stocks JNJ flat PFE flat ABT flat MRK +0.16% AMGN flat Health care shares were generally flat in pre market trade Monday. In health care stocks news, Merck & Company ( MRK ) a pharmaceutical company,